Cargando…

Levamisole-induced and COVID-19-induced retiform purpura: two overlapping, emerging clinical syndromes

Levamisole exposure in cocaine users is a well-recognized cause of retiform purpura, a distinctive net-like maculopapular patch. Prolonged exposure to levamisole can lead to a serious systemic syndrome known as levamisole-induced vasculitis, most commonly involving the kidneys and lungs. More recent...

Descripción completa

Detalles Bibliográficos
Autores principales: Keim, Catherine K., Schwartz, Robert A., Kapila, Rajendra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8607060/
https://www.ncbi.nlm.nih.gov/pubmed/34807290
http://dx.doi.org/10.1007/s00403-021-02303-1
_version_ 1784602477794951168
author Keim, Catherine K.
Schwartz, Robert A.
Kapila, Rajendra
author_facet Keim, Catherine K.
Schwartz, Robert A.
Kapila, Rajendra
author_sort Keim, Catherine K.
collection PubMed
description Levamisole exposure in cocaine users is a well-recognized cause of retiform purpura, a distinctive net-like maculopapular patch. Prolonged exposure to levamisole can lead to a serious systemic syndrome known as levamisole-induced vasculitis, most commonly involving the kidneys and lungs. More recently, retiform purpura has been observed in patients with the novel coronavirus disease of 2019 (COVID-19). Due to their overlapping dermatologic and systemic manifestations, levamisole-induced and COVID-19-induced retiform purpura may mimic one another in clinical presentation. The possibility that patients may present with one or both syndromes creates a diagnostic challenge. This review of levamisole-induced and COVID-19-induced retiform purpura highlights their corresponding and distinctive features. Additionally, we propose a unique staging system for levamisole-induced retiform purpura that may be valid for future classification of COVID-19-induced retiform purpura.
format Online
Article
Text
id pubmed-8607060
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-86070602021-11-22 Levamisole-induced and COVID-19-induced retiform purpura: two overlapping, emerging clinical syndromes Keim, Catherine K. Schwartz, Robert A. Kapila, Rajendra Arch Dermatol Res Concise Communications Levamisole exposure in cocaine users is a well-recognized cause of retiform purpura, a distinctive net-like maculopapular patch. Prolonged exposure to levamisole can lead to a serious systemic syndrome known as levamisole-induced vasculitis, most commonly involving the kidneys and lungs. More recently, retiform purpura has been observed in patients with the novel coronavirus disease of 2019 (COVID-19). Due to their overlapping dermatologic and systemic manifestations, levamisole-induced and COVID-19-induced retiform purpura may mimic one another in clinical presentation. The possibility that patients may present with one or both syndromes creates a diagnostic challenge. This review of levamisole-induced and COVID-19-induced retiform purpura highlights their corresponding and distinctive features. Additionally, we propose a unique staging system for levamisole-induced retiform purpura that may be valid for future classification of COVID-19-induced retiform purpura. Springer Berlin Heidelberg 2021-11-22 2023 /pmc/articles/PMC8607060/ /pubmed/34807290 http://dx.doi.org/10.1007/s00403-021-02303-1 Text en © The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2021 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Concise Communications
Keim, Catherine K.
Schwartz, Robert A.
Kapila, Rajendra
Levamisole-induced and COVID-19-induced retiform purpura: two overlapping, emerging clinical syndromes
title Levamisole-induced and COVID-19-induced retiform purpura: two overlapping, emerging clinical syndromes
title_full Levamisole-induced and COVID-19-induced retiform purpura: two overlapping, emerging clinical syndromes
title_fullStr Levamisole-induced and COVID-19-induced retiform purpura: two overlapping, emerging clinical syndromes
title_full_unstemmed Levamisole-induced and COVID-19-induced retiform purpura: two overlapping, emerging clinical syndromes
title_short Levamisole-induced and COVID-19-induced retiform purpura: two overlapping, emerging clinical syndromes
title_sort levamisole-induced and covid-19-induced retiform purpura: two overlapping, emerging clinical syndromes
topic Concise Communications
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8607060/
https://www.ncbi.nlm.nih.gov/pubmed/34807290
http://dx.doi.org/10.1007/s00403-021-02303-1
work_keys_str_mv AT keimcatherinek levamisoleinducedandcovid19inducedretiformpurpuratwooverlappingemergingclinicalsyndromes
AT schwartzroberta levamisoleinducedandcovid19inducedretiformpurpuratwooverlappingemergingclinicalsyndromes
AT kapilarajendra levamisoleinducedandcovid19inducedretiformpurpuratwooverlappingemergingclinicalsyndromes